Karma Biotechnologies

company

About

Karma Biotechnologies is solving autoimmunity, allergies, and food sensitivities with our Xavine™ precision immunotherapy platform.

  • 1 - 10

Details

Last Funding Type
Seed
Last Funding Money Raised
$2.78M
Industries
Biotechnology
Founded date
Mar 21, 2017
Number Of Employee
1 - 10
Operating Status
Active

Karma Biotechnologies is a Los Angeles startup dedicated to solving autoimmunity, allergies, and food sensitivities with our Xavine™ precision immunotherapy platform. General immune suppression is still the standard of care for most autoimmune disease patients; there is a critical unmet need to develop antigen-specific therapies that inhibit only the disease-causing rogue immune cells. To meet this need, Karma is leveraging expertise in immunology and lipid nanoparticle engineering to develop tolerogenic immunotherapies that elicit antigen-specific immune tolerance in vivo.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$2.78M
Karma Biotechnologies has raised a total of $2.78M in funding over 2 rounds. Their latest funding was raised on Sep 1, 2021 from a Seed round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 1, 2021 Seed $2.78M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Karma Biotechnologies is funded by 1 investors. Gaingels are the most recent investors.
Investor Name Lead Investor Funding Round
Gaingels Seed